{
    "nctId": "NCT05677308",
    "briefTitle": "LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)",
    "officialTitle": "LYNPARZA Tablets 100mg, 150mg General Drug Use-results Study in Patients With BRCA Mutated HER2 Negative High Recurrent Risk Breast Cancer in the Adjuvant Setting",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 104,
    "primaryOutcomeMeasure": "Incidence of bone marrow suppression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patients who started treatment with LYNPARZA for the first time for the approved indication \"Adjuvant treatment for patients with BRCA-mutated HER2 negative high recurrent risk breast cancer\"\n\nExclusion Criteria:\n\n* Patients who have no treatment history with LYNPARZA",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}